Fresenius Kabi announced the launch of Argatroban Injection.

Argatroban is a thrombin inhibitor anticoagulant currently indicated as prophylaxis and treatment of thrombosis in heparin-induced thrombocytopenia (HIT) or in those with or at risk of HIT undergoing percutaneous coronary intervention (PCI). Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.

RELATED: New Algorithm to Guide Antiplatelet Tx Post-PCI

Argatroban Injection is available as a 250mg/2.5mL strength in single-dose vials.

For more information call (888) 386-1300 or visit